tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFs
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

DRMA Stock Latest News

Dermata Therapeutics Begins Manufacturing for STAR-2 Trial
Company AnnouncementsDermata Therapeutics Begins Manufacturing for STAR-2 Trial
25d ago
8K
DRMA
Dermata Therapeutics price target lowered to $3 from $6 at Maxim
PremiumThe Fly
Dermata Therapeutics price target lowered to $3 from $6 at Maxim
25d ago
DRMA
Dermata Faces Nasdaq Delisting Risk Over Bid Price
PremiumCompany Announcements
Dermata Faces Nasdaq Delisting Risk Over Bid Price
30d ago
8K
DRMA
Dermata Reports Positive Phase 3 Trial Results
PremiumCompany Announcements
Dermata Reports Positive Phase 3 Trial Results
1M ago
8K
DRMA
Dermata Therapeutics reports Q1 EPS (45c) vs. ($7.06) last year
PremiumThe Fly
Dermata Therapeutics reports Q1 EPS (45c) vs. ($7.06) last year
1M ago
DRMA
Dermata Therapeutics sees cash runway into 1Q26
PremiumThe FlyDermata Therapeutics sees cash runway into 1Q26
1M ago
DRMA
Optimistic Buy Rating for Dermata Therapeutics Driven by Promising Phase 3 Trial Results and Strong Financial Position
Premium
Ratings
Optimistic Buy Rating for Dermata Therapeutics Driven by Promising Phase 3 Trial Results and Strong Financial Position
2M ago
DRMA
Dermata Therapeutics files to sell 10.01M shares of common stock for holders
Premium
The Fly
Dermata Therapeutics files to sell 10.01M shares of common stock for holders
2M ago
DRMA
Dermata’s XYNGARI trial hits statistically significant difference at 4 weeks
PremiumThe Fly
Dermata’s XYNGARI trial hits statistically significant difference at 4 weeks
2M ago
DRMA
Buy Rating for Dermata Therapeutics: Promising Phase 3 Results and Strategic Advantages
PremiumRatings
Buy Rating for Dermata Therapeutics: Promising Phase 3 Results and Strategic Advantages
3M ago
DRMA
Dermata Therapeutics’ xyngari in acne meets all primary Phase 3 endpoints
PremiumThe Fly
Dermata Therapeutics’ xyngari in acne meets all primary Phase 3 endpoints
3M ago
DRMA
Dermata Therapeutics announces last patient visit in Phase 3 acne trial
PremiumThe Fly
Dermata Therapeutics announces last patient visit in Phase 3 acne trial
3M ago
DRMA
Dermata Therapeutics receives notice of acceptance for Australian patent
PremiumThe FlyDermata Therapeutics receives notice of acceptance for Australian patent
4M ago
DRMA
APO accepts Dermata’s patent application for DMT410 program for hyperhidrosis
Premium
The Fly
APO accepts Dermata’s patent application for DMT410 program for hyperhidrosis
4M ago
DRMA
Dermata Therapeutics files to sell 1.94M shares of common stock for holders
Premium
The Fly
Dermata Therapeutics files to sell 1.94M shares of common stock for holders
5M ago
DRMA
Biotech Alert: Searches spiking for these stocks today
PremiumThe Fly
Biotech Alert: Searches spiking for these stocks today
5M ago
INM
IPA
Biotech Alert: Searches spiking for these stocks today
PremiumThe Fly
Biotech Alert: Searches spiking for these stocks today
5M ago
INM
MGX
Dermata Therapeutics to prices 2M shares at $1.27 in private placement
PremiumThe Fly
Dermata Therapeutics to prices 2M shares at $1.27 in private placement
5M ago
DRMA
Dermata Therapeutics receives FDA approval for Xyngari proprietary name
PremiumThe Fly
Dermata Therapeutics receives FDA approval for Xyngari proprietary name
6M ago
DRMA
Dermata Therapeutics completes enrollment in DMT310 Phase 3 STAR-1 trial
PremiumThe FlyDermata Therapeutics completes enrollment in DMT310 Phase 3 STAR-1 trial
6M ago
DRMA
Dermata Therapeutics files to sell 5.87M shares of common stock for holders
Premium
The Fly
Dermata Therapeutics files to sell 5.87M shares of common stock for holders
9M ago
DRMA
Morning Movers: Intel jumps after announcing AWS collaboration
Premium
The Fly
Morning Movers: Intel jumps after announcing AWS collaboration
9M ago
BFI
CMP

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >